Inovio Pharmaceuticals Inc.'s DNA-based Zika vaccine, GLS-5700, invoked an immune response and was considered to have a positive safety profile in its first human study.
Inovio had previously released data indicating that the vaccine protected animals from the infection.
In the phase 1 clinical trial, known as ZIKA-001, the vaccine induced high levels of binding antibodies in 100% of participants.
"Results from this published study demonstrate that all human subjects responded to the vaccine and that the immune responses have the ability to confer protection in challenge models. A second phase 1 study, now fully enrolled in Puerto Rico, is designed with a placebo control to explore a potential trend towards clinical efficacy," Inovio President and CEO J. Joseph Kim said in a statement.
Inovio is developing GLS-5700 in collaboration with GeneOne Life Science Inc. and The Wistar Institute.
It is also studying the vaccine for dengue virus-positive individuals.